Aprea Therapeutics Inc (APRE)

$1.50 -0.04 (-2.39%)
Market Cap 8.68M
Revenue (ttm) 1.50M
Net Income (ttm) -12.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -864.00%
Debt to Equity Ratio 0.00
Volume 11,500
Avg Vol 25,756
Day's Range N/A - N/A
Shares Out 5.49M
Stochastic %K 6%
Beta 1.04
Analysts Strong Sell
Price Target $13.67

Latest News on APRE

Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial

Mar 31, 2025, 8:30 AM EDT - 18 days ago

Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial

Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Mar 25, 2025, 8:30 AM EDT - 24 days ago

Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)

Mar 11, 2025, 8:30 AM EDT - 5 weeks ago

Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)

Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics

Feb 5, 2025, 8:00 AM EST - 2 months ago

Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics

Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward

Dec 11, 2024, 8:30 AM EST - 4 months ago

Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward

Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

Oct 23, 2024, 8:30 AM EDT - 6 months ago

Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit

Oct 14, 2024, 8:30 AM EDT - 6 months ago

Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

Oct 10, 2024, 8:30 AM EDT - 6 months ago

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development

Oct 9, 2024, 8:30 AM EDT - 6 months ago

Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development

UPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

Sep 9, 2024, 5:15 PM EDT - 7 months ago

UPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

Sep 9, 2024, 4:05 PM EDT - 7 months ago

Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 12, 2024, 8:30 AM EDT - 8 months ago

Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024

Jun 21, 2024, 8:00 AM EDT - 10 months ago

Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024

Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051

Jun 17, 2024, 8:30 AM EDT - 10 months ago

Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051

Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial

May 28, 2024, 8:45 AM EDT - 11 months ago

Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial

Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update

May 14, 2024, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update

Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference

May 13, 2024, 4:01 PM EDT - 1 year ago

Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference

Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D.

May 2, 2024, 9:15 AM EDT - 1 year ago

Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D.

Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024

Apr 10, 2024, 12:00 PM EDT - 1 year ago

Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024

Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Mar 26, 2024, 7:45 AM EDT - 1 year ago

Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Karolinska Development's portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million

Mar 14, 2024, 7:48 AM EDT - 1 year ago

Karolinska Development's portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million

Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million

Mar 11, 2024, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million

Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers

Mar 11, 2024, 8:29 AM EDT - 1 year ago

Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers

Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024

Mar 5, 2024, 4:45 PM EST - 1 year ago

Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024

Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor

Feb 6, 2024, 8:01 AM EST - 1 year ago

Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor

Aprea Therapeutics to Present at DDR Inhibitors Summit 2024

Jan 30, 2024, 8:00 AM EST - 1 year ago

Aprea Therapeutics to Present at DDR Inhibitors Summit 2024

Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024

Jan 4, 2024, 4:05 PM EST - 1 year ago

Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024

Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

Nov 9, 2023, 4:05 PM EST - 1 year ago

Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio

Oct 16, 2023, 8:30 AM EDT - 1 year ago

Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio

Aprea Therapeutics Announces Two Posters at the Upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 19, 2023, 8:00 AM EDT - 1 year ago

Aprea Therapeutics Announces Two Posters at the Upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Aprea Announces Preclinical Data Supporting Highly Differentiated WEE1 Inhibitor, ATRN-1051, Relative To Other WEE1 Inhibitors

Sep 11, 2023, 8:00 AM EDT - 1 year ago

Aprea Announces Preclinical Data Supporting Highly Differentiated WEE1 Inhibitor, ATRN-1051, Relative To Other WEE1 Inhibitors

Aprea Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 6, 2023, 4:05 PM EDT - 1 year ago

Aprea Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman

Aug 24, 2023, 7:30 AM EDT - 1 year ago

Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman

Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations

Aug 10, 2023, 7:30 AM EDT - 1 year ago

Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations

Aprea Therapeutics to Present at Maxim Virtual Healthcare Conference

Jun 14, 2023, 8:00 AM EDT - 2 years ago

Aprea Therapeutics to Present at Maxim Virtual Healthcare Conference

Aprea Therapeutics to Present at BIO International Convention

May 30, 2023, 8:30 AM EDT - 2 years ago

Aprea Therapeutics to Present at BIO International Convention

Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations

May 15, 2023, 4:05 PM EDT - 2 years ago

Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations

Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of Directors

May 8, 2023, 8:00 AM EDT - 2 years ago

Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of Directors

Aprea Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Update on Business Operations

Mar 30, 2023, 4:05 PM EDT - 2 years ago

Aprea Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Update on Business Operations

Aprea Therapeutics Announces Presentation of Preclinical Data on Pipeline Programs at the AACR 2023 Annual Meeting

Mar 16, 2023, 8:00 AM EDT - 2 years ago

Aprea Therapeutics Announces Presentation of Preclinical Data on Pipeline Programs at the AACR 2023 Annual Meeting

Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Mar 1, 2023, 4:05 PM EST - 2 years ago

Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Aprea Therapeutics Announces Closing of $5.5 Million Underwritten Public Offering of Common Stock

Feb 27, 2023, 4:05 PM EST - 2 years ago

Aprea Therapeutics Announces Closing of $5.5 Million Underwritten Public Offering of Common Stock

Aprea Therapeutics Announces Pricing of $5.5 Million Underwritten Public Offering of Common Stock

Feb 22, 2023, 8:41 PM EST - 2 years ago

Aprea Therapeutics Announces Pricing of $5.5 Million Underwritten Public Offering of Common Stock

Aprea Therapeutics Announces One-for-Twenty Reverse Stock Split

Feb 13, 2023, 7:00 AM EST - 2 years ago

Aprea Therapeutics Announces One-for-Twenty Reverse Stock Split

Aprea Therapeutics Appoints John Hamill as Chief Financial Officer

Jan 30, 2023, 8:00 AM EST - 2 years ago

Aprea Therapeutics Appoints John Hamill as Chief Financial Officer

Aprea Therapeutics to Participate in 6th Annual DNA Damage and Response (DDR) Inhibitors Summit

Jan 19, 2023, 8:00 AM EST - 2 years ago

Aprea Therapeutics to Participate in 6th Annual DNA Damage and Response (DDR) Inhibitors Summit

Karolinska Development's portfolio company Aprea Therapeutics doses the first patient in a clinical phase 1/2a study of ATRN-119

Jan 12, 2023, 5:39 AM EST - 2 years ago

Karolinska Development's portfolio company Aprea Therapeutics doses the first patient in a clinical phase 1/2a study of ATRN-119

Aprea Therapeutics Reports Third Quarter 2022 Financial Results and Provides Update on Business Operations

Nov 9, 2022, 4:15 PM EST - 2 years ago

Aprea Therapeutics Reports Third Quarter 2022 Financial Results and Provides Update on Business Operations

Aprea Therapeutics Announces Poster Presentation at the 2022 Rivkin Center and American Association for Cancer (AACR) Virtual Ovarian Cancer Research Seminar Series

Sep 22, 2022, 6:00 PM EDT - 2 years ago

Aprea Therapeutics Announces Poster Presentation at the 2022 Rivkin Center and American Association for Cancer (AACR) Virtual Ovarian Cancer Research Seminar Series

Aprea Therapeutics Reports Second Quarter 2022 Financial Results and Provides Update on Business Operations

Aug 11, 2022, 4:15 PM EDT - 2 years ago

Aprea Therapeutics Reports Second Quarter 2022 Financial Results and Provides Update on Business Operations